British Journal of Cancer

FIGURES AND TABLES

FROM:

Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study

F Strasser, T A Lutz, M T Maeder, B Thuerlimann, D Bueche, M Tschöp, K Kaufmann, B Holst, M Brändle, R von Moos, R Demmer and T Cerny

BACK TO ARTICLE
Figure 1 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Figure 1.

Flow of patients in a randomised, placebo-controlled, double-blind, double-crossover trial of i.v. ghrelin for cancer-related anorexia/cachexia.

Full figure and legend (55K)
Figure 2 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Figure 2.

Pharmacokinetics of active and total ghrelin of the upper dose patients. BL, baseline; I-V, blood samples week 1 (I: morning fasting; II: immediately before ghrelin infusion (1030); III: during ghrelin infusion; IV: after ghrelin infusion (1130); V: after lunch (1230)); Ia-Va, blood samples week 2; EOS, end of study. P<0.001 for differences of morning fasting level of total ghrelin 3 days after ghrelin or placebo.

Full figure and legend (114K)
Table 1 - Demographics of 21 patients with cancer-related anorexia//cachexia - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Table 1 - Demographics of 21 patients with cancer-related anorexia/cachexia.

Full table
Table 2 - Adverse events of treatment with intravenous ghrelin in 21 patients with cancer-related anorexia//cachexia - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Table 2 - Adverse events of treatment with intravenous ghrelin in 21 patients with cancer-related anorexia/cachexia.

Full table
Table 3 - Patients' preference of treatment between placebo and intravenous ghrelin - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Table 3 - Patients' preference of treatment between placebo and intravenous ghrelin.

Full table
BACK TO ARTICLE